SmithKline Beecham's fee to Quest Diagnostics for Category One use (inside SmithKline and in its own disease programs) of Quest's encoded laboratory data, first licence period
US $50,000
USD per year (stated as $50,000 a month), US
“certain non-exclusive and limited-use license rights on economically preferred terms for a limited term for the clinical laboratory data identified herein ... SmithKline Beecham shall pay to Quest Diagnostics in advance and in full, promptly after the Commencement Date, a fee of fifty thousand U.S. Dollars (US $50,000) per month ... provided that in no event shall the aggregate fee for such period exceed $625,000.”
- Kind of source
- Regulatory filing
- Read on
- 2026-11-06
- Daily check
- Quote found at the source on 2026-11-06
- What to know
- A realised lab-data licence, but granted as a condition of Quest buying SmithKline's clinical lab business, on terms the agreement itself calls economically preferred, so below an arm's-length price. It covers de-identified (encoded) historical and daily lab results and states no volume, so no per-test price follows. After the first 18 months the fee is reset to the lowest price Quest charges other drug companies for similar data, capped at $500,000 a year in the initial term, with no charge for purely internal use.
- Arithmetic
- $50,000 x 12 months = $600,000 a year; the first period (to the 18-month anniversary) was capped at $625,000 in total.
- About
- Lab results
Used in
Kept as evidence; no figure on the platform is computed from it yet.